Evidence map›Paper›PMID 38105902›Full record

ReviewFrontiers in medicine2023

Treatment and practical considerations of diabetic kidney disease.

Yara Bilen, Allaa Almoushref, Kenda Alkwatli, Omar Osman, Ali Mehdi, Hanny Sawaf

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Diabetic nephropathy: Role of nitric oxide.Nitric oxide : biology and chemistry · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yara BilenCleveland Clinic, Department of Internal Medicine, Cleveland, OH, United States.
Allaa AlmoushrefCleveland Clinic, Department of Kidney Medicine, Cleveland, OH, United States.
Kenda AlkwatliCleveland Clinic, Department of Endocrinology, Cleveland, OH, United States.
Omar OsmanCleveland Clinic, Department of Kidney Medicine, Cleveland, OH, United States.
Ali Mehdi *Cleveland Clinic, Department of Kidney Medicine, Cleveland, OH, United States.
Hanny Sawaf *Cleveland Clinic, Department of Kidney Medicine, Cleveland, OH, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is a complication of diabetes that can lead to kidney failure. Over the years, several drugs have been developed to combat this disease. In the early 90s, angiotensin blockade (ACEi and ARBs) was introduced, which revolutionized the treatment of DKD. In recent years, newer drugs such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, endothelin antagonists, and mineralocorticoid receptor antagonists (MRA) have shown great promise in reducing albuminuria and protecting the kidneys. These drugs are being used in combination with lifestyle modifications, patient education, and risk factor modification to effectively manage DKD. In this review, we will explore the latest pharmacological options, their efficacy, and their potential to revolutionize the management of this debilitating disease.

Indexed as

chronic kidney diseasediabetesdiabetic kidney diseasediabetic nephropathyfinerenoneGLP-1 receptor agonistSGLT2 inhibitor

Identifiers

PMID38105902
PMCPMC10722293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.